Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19

Giuseppe Mancia; Federico Rea; Monica Ludergnani; Giovanni Apolone; Giovanni Corrao

doi:10.1056/nejmoa2006923

Abstract

In this large, population-based study, the use of ACE inhibitors and ARBs was more frequent among patients with Covid-19 than among controls because of their higher prevalence of cardiovascular disease. However, there was no evidence that ACE inhibitors or ARBs affected the risk of COVID-19.

Keywords

Renin–angiotensin systemCoronavirus disease 2019 (COVID-19)AldosteroneInternal medicineAngiotensin Receptor BlockersMedicinePharmacologyBlood pressureDisease

Affiliated Institutions

Related Publications

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

Muthiah Vaduganathan , Orly Vardeny , Thomas Michel +3 more

RAAS Inhibitors in Patients with Covid-19 The effects of renin–angiotensin–aldosterone system blockers on angiotensin-converting enzyme 2 levels and activity in humans are uncer...

2020 New England Journal of Medicine 2138 citations

Angiotensin-converting enzyme inhibitor and spironolactone combination therapy

Faïez Zannad

Secondary aldosteronism has deleterious effects in patients with congestive heart failure (CHF) and can contribute to congestion, ventricular arrhythmias, and sudden death. Mort...

1993 The American Journal of Cardiology 38 citations

Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2

Carlos M. Ferrario , Jewell A. Jessup , Mark C. Chappell +5 more

Background— Angiotensin-converting enzyme 2 (ACE2) has emerged as a novel regulator of cardiac function and arterial pressure by converting angiotensin II (Ang II) into the vaso...

2005 Circulation 1598 citations

Evidence of a Partial Escape of Renin‐Angiotensin‐Aldosterone Blockade in Patients with Acute Myocardial Infarction Treated with Ace Inhibitors

Claudio Borghi , Stefano Boschi , Ettore Ambrosioni +3 more

Angiotensin‐Converting enzyme (ACE) inhibitors have been designed to block the renin‐angiotensin system and can represent an effective therapeutic approach in those settings whe...

1993 The Journal of Clinical Pharmacology 138 citations

Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction

James B. Young , Mark E. Dunlap , Marc A. Pfeffer +15 more

Background— Patients with symptomatic chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF) have a high risk of death and hospitalization for CHF det...

2004 Circulation 393 citations

Publication Info

Year: 2020
Type: article
Volume: 382
Issue: 25
Pages: 2431-2440
Citations: 1098
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1098

OpenAlex

Cite This

APA Style

                            
                                
                                    Giuseppe Mancia, 
                                
                                    Federico Rea, 
                                
                                    Monica Ludergnani
                                
                                et al.
                            
                            (2020). 
                            Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19. 
                            New England Journal of Medicine
                            , 382
                            (25)
                            , 2431-2440.
                            https://doi.org/10.1056/nejmoa2006923
                        

Identifiers

DOI: 10.1056/nejmoa2006923